| 摘要 |
Lysergic acids derivs. of formula (I) and their acid addn. salts are novel cpds. (where R is 3-pyridyl, x y is -CH=C and the -CH2SR gp. has beta configuration or R is 2-pyridyl, x y is -CH=C or -CH2-CH and the -CH2SR gp. has alpha-configuration). Cpds. (I) are administered orally rectally or parenterally in daily doses of 1-100mg taken as one or several unit doses. The central dopaminergis stimulatory activity is potentialised by phosphodiesterase inhibitors such as theophylline, caffeine, 4-amino-1H-pyrazolo(3,4-b)pyridine-5-carboxylic acid derivs, 4-(3,4-dimethoxybenzyl)-2-imidazolidinone and analogous derivs and minor tranquillisers such as benzodiazepines and dibenzazepines (I) may be administered, with the phosphodiesterase inhibitor, in daily doses of 0.5-50mg; the ratio (I):phosphodiesterase inhibitor being 1:10 to 1:50. The three cpds. which may be prepd. by the methods of the parent patent comprise 6-methyl-8 beta-(3-pyridylthiometyl)DELTA 9-ergolene, 6-methyl-5 alpha-(2-pyridylthiomethyl)-ergoline and 6-methyl-8 alpha-(2-pyridylthiomethyl)-DELTA 9-ergolene. |
